It was reported on Tuesday that CATO SMS, a company focused on specialised clinical research solutions, has acquired United States-based Array Biostatistics.
This move is to help CATO SMS expand its full-service biostatistical consulting, analysis and programming capabilities. CATO SMS is to concentrate on building its team of senior biostaticians and statistical programmers as part of its expansion plans.
Array will continue to be led by Sandy Ferber, chief executive officer of Array. Ferber will also lead CATO SMS' overall biometrics offering.
Mirecule expands collaboration with Sanofi to advance FSHD therapy
Sanofi's venglustat receives FDA Breakthrough Therapy designation for type 3 Gaucher disease
Alebund Pharmaceuticals signs licensing and equity agreements with R1 Therapeutics
Apertura Gene Therapy agrees manufacturing collaboration with Viralgen
Humacyte submits Israel MAA for Symvess arterial trauma repair
Sentynl Therapeutics and PRG S&T enter licensing agreement for potential HGPS treatment
NeuroSense Therapeutics reports Phase 2b trial results of PrimeC in ALS
Imfinzi approved in EU for perioperative treatment of early gastric and gastroesophageal cancers
LynxKite Technologies expands Biophytis collaboration
BioDlink named 'Emerging CDMO of the Year' at Asia-Pacific Biopharma Excellence Awards
Vimgreen Pharmaceuticals receives IND clearance for VG081821 in China
Emerald Clinical Trials honoured with 2026 Asia Pacific Biopharma Excellence Award